Guy C Toner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2333818/publications.pdf

Version: 2024-02-01

54 1,876 21 43
papers citations h-index g-index

54 54 54 2288 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. Journal of Clinical Oncology, 2011, 29, 4541-4547.	1.6	293
2	Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel. Gynecologic Oncology, 1996, 63, 89-93.	1.4	238
3	A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiotherapy and Oncology, 1999, 52, 129-136.	0.6	140
4	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. Journal of Clinical Oncology, 2013, 31, 3490-3493.	1.6	124
5	ACCURACY OF COMPUTED TOMOGRAPHY GUIDED CORE NEEDLE BIOPSY OF MUSCULOSKELETAL TUMOURS. ANZ Journal of Surgery, 2005, 75, 187-191.	0.7	116
6	Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer, 1991, 67, 2049-2057.	4.1	97
7	Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 476-480.	2.5	80
8	The prevalence and correlates of supportive care needs in testicular cancer survivors: a crossâ€sectional study. Psycho-Oncology, 2013, 22, 2557-2564.	2.3	65
9	Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 2010, 102, 1253-1262.	6.3	64
10	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship, 2016, 10, 223-233.	2.9	57
11	A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psycho-Oncology, 2018, 27, 1129-1137.	2.3	54
12	Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene, 2004, 23, 1618-1626.	5.9	50
13	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anti-Cancer Drugs, 2008, 19, 547-552.	1.4	48
14	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 338-341.	1.3	46
15	Improved haematopoietic recovery following transplantation with ex vivo -expanded mobilized blood cells*. British Journal of Haematology, 2004, 126, 536-545.	2.5	39
16	Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging, 2005, 5, 66-72.	2.8	37
17	PET for Sarcomas Other Than Gastrointestinal Stromal Tumors. Oncologist, 2008, 13, 22-26.	3.7	32
18	Sarcoidosis, "sarcoid-like lymphadenopathy,―and testicular germ cell tumors. American Journal of Medicine, 1990, 89, 651-656.	1.5	31

#	Article	IF	CITATIONS
19	Genderâ€specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. International Journal of Cancer, 2009, 125, 426-431.	5.1	31
20	Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Investigational New Drugs, 2005, 23, 253-256.	2.6	27
21	Composite Lymphoma. American Journal of Clinical Pathology, 1986, 86, 375-378.	0.7	22
22	Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. International Journal of Cardiology, 2009, 131, e92-e94.	1.7	22
23	Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S444-S455.	1.0	17
24	The management of testicular cancer in Victoria, 1988–1993. Medical Journal of Australia, 2001, 174, 328-331.	1.7	14
25	Patterns of management and surveillance imaging amongst medical oncologists in <scp>A</scp> ustralia for stage <scp>I</scp> testicular cancer. BJU International, 2013, 112, E35-43.	2.5	14
26	Chemotherapy for soft tissue sarcomas. Acta Orthopaedica, 1997, 68, 133-138.	1.4	11
27	Pharmacodynamic analysis of tumour perfusion assessed by 150-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI Research, 2012, 2, 31.	2.5	10
28	Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 277-282.	1.3	9
29	Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use. Journal of Clinical Oncology, 2004, 22, 3842-3845.	1.6	9
30	MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER IN VICTORIA, 1990-1995. ANZ Journal of Surgery, 2006, 76, 113-119.	0.7	8
31	Clinical Relevance of "Late―in the Management of Late Relapse After Treatment for a Germ Cell Tumor. Journal of Clinical Oncology, 2008, 26, 5502-5503.	1.6	8
32	Ovarian Growing Teratoma Syndrome With Spuriously Elevated α-Fetoprotein. Journal of Clinical Oncology, 2015, 33, e99-e100.	1.6	8
33	Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer, 2018, 18, 854.	2.6	7
34	Pulmonary function testing for the early detection of drugâ€induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity. Internal Medicine Journal, 2020, 50, 1311-1325.	0.8	7
35	MANAGEMENT OF SUPERFICIAL BLADDER CANCER IN VICTORIA: 1990 AND 1995. ANZ Journal of Surgery, 2005, 75, 270-274.	0.7	5
36	Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. International Seminars in Surgical Oncology, 2005, 2, 12.	1.1	5

#	Article	IF	Citations
37	Lethal skin cancers in hairy cell leukemia (two case reports). European Journal of Haematology, 1987, 39, 82-85.	2.2	5
38	Chronic Hiccups Following Chemotherapy. Journal of Pain and Symptom Management, 1999, 18, 387-388.	1.2	4
39	Late Relapsing Stage I Nonseminoma. Journal of Clinical Oncology, 2008, 26, 5647-5648.	1.6	4
40	Online psychological self-management intervention for testicular cancer survivors (e-TC 2.0): promising acceptability and preliminary efficacy, but limited feasibility. Journal of Psychosocial Oncology Research and Practice, 2020, 2, e33.	0.5	4
41	The blood-brain barrier and response of C.N.S. metastases to chemotherapy. Journal of Neuro-Oncology, 1989, 7, 21-24.	2.9	3
42	A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. Investigational New Drugs, 1999, 17, 73-80.	2.6	3
43	Optimal management of stage I seminoma in 2015. Nature Reviews Urology, 2015, 12, 249-251.	3.8	2
44	Poor prognosis germ-cell tumors: An unresolved challenge. Urologic Oncology, 2002, 20, 251-261.	1.5	2
45	Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer. Prostate Journal, 2001, 3, 30-35.	0.2	1
46	The Challenge of Poor-Prognosis Germ Cell Tumors. Urologic Clinics of North America, 2007, 34, 187-197.	1.8	1
47	Dose Escalation Study of Carboplatin and Cyclophosphamide With Filgrastim Support. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 263-269.	1.3	1
48	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial Journal of Clinical Oncology, 2018, 36, 5040-5040.	1.6	1
49	Three and four cycles of bleomycin, etoposide and cisplatinare equivalent in the treatment of good prognosis germ cell cancer. Evidence-based Oncology, 2001, 2, 188-190.	0.1	O
50	Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 148-155.	1.1	0
51	The <scp>A</scp> ustralian and <scp>N</scp> ew <scp>Z</scp> ealand <scp>U</scp> rogenital and <scp>P</scp> rostate (<scp>ANZUP</scp>) <scp>C</scp> ancer <scp>T</scp> rials <scp>G</scp> roup – a new coâ€operative cancer trials group in genitourinary oncology. BJU International, 2015, 115, 856-858.	2.5	0
52	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs) Journal of Clinical Oncology, 2018, 36, TPS4596-TPS4596.	1.6	0
53	The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study Journal of Clinical Oncology, 2018, 36, 2563-2563.	1.6	0
54	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) Journal of Clinical Oncology, 2019, 37, TPS539-TPS539.	1.6	0